EUVIMEDOpdag EUVIMED
Crossref

Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity

Kelli A Lytle, Jin Ook Chung, Nikki C Bush, Jessica M Triay, Michael D Jensen iD

Lipids · 2023-05 · 58 (3) · 107-115

DOI: 10.1002/lipd.12367 ↗

At a glance

Journal article in Lipids, published online on 2023-02-27. Written by Kelli A Lytle and 4 co-authors. Institution: Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Obesity, Morbid, Insulin Resistance. Cited 7 times so far (Crossref); 36 references. Funded by: NCRR NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We investigated the relationships between ceramide species concentrations in liver, plasma and very low‐density lipoproteins (VLDL) particles of humans with obesity as well as the relationships between hepatic fat content and hepatic ceramide concentrations and proportional distribution. Twenty‐five obese (body mass index >35 kg/m 2 ) adults participated in this study. Plasma, VLDL and hepatocellular ceramide concentrations were measured by liquid chromatography/tandem mass spectrometry. The proportionate distribution of measured ceramide species differed between liver, whole plasma and the VLDL fraction. We found significant, positive correlations between the proportion of C14:0, C18:0, C20:0 and C24:1 ceramide in the liver and whole plasma ( γ = 0.491, p = 0.013; γ = 0.573, p = 0.003; γ = 0.479, p = 0.015; γ = 0.716, p = 0.00006; respectively). In contrast, only the proportional contribution of C24:1 ceramide correlated positively between VLDL and liver ( γ = 0.425, p = 0.013). The percent hepatic fat correlated positively with the proportion of C18:1, C18:0 and C20:0 hepatic ceramides ( γ = 0.415, p = 0.039; γ = 0.426, p = 0.034; γ = 0.612, p = 0.001; respectively), but not with total hepatic ceramide concentration. The proportions of whole plasma ceramide subspecies, especially C14:0, C18:0, C20:0 and C24:1chain length, are reflective of those of hepatic ceramide subspecies in obese humans; these appear to be markers of hepatic ceramide species composition.

Subjects

MeSH terms (MEDLINE)

Obesity, MorbidInsulin ResistanceHumansAdultCeramidesLipoproteins, VLDLObesityLiverLipoproteins, LDL

Author keywords

VLDLceramidesfatty liverobesity

Substances

CeramidesLipoproteins, VLDLLipoproteins, LDL

Authors and institutions

  • Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Chonnam National University Medical School, Gwangju, Republic of Korea.
  • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Bendigo Health, Bendigo, Victoria, Australia.

ORCID profiles: Michael D Jensen

Funding

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • American Diabetes Association

Cite

APA

Lytle, K. A., Chung, J. O., Bush, N. C., Triay, J. M., & Jensen, M. D. (2023). Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity. Lipids, 58(3), 107-115. https://doi.org/10.1002/lipd.12367

Vancouver

Lytle KA, Chung JO, Bush NC, Triay JM, Jensen MD. Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity. Lipids. 2023;58(3):107-115. doi:10.1002/lipd.12367

BibTeX
@article{Lytle2023,
  author = {Lytle, Kelli A and Chung, Jin Ook and Bush, Nikki C and Triay, Jessica M and Jensen, Michael D},
  title = {Ceramide concentrations in liver, plasma, and very low‐density lipoproteins of humans with severe obesity},
  journal = {Lipids},
  year = {2023},
  volume = {58},
  number = {3},
  pages = {107--115},
  doi = {10.1002/lipd.12367}
}
Start for free →